19 October 2026

strategyland.uk

BioPharma Credit PLC (BPCR)

Rank #7 of 280 - Financials - UK Equities

Home/Stocks/Financials

BioPharma Credit PLC

BPCR.L·Financials·Market Cap £1.1b

Rank #7 of 280

Quantitative Model · 280 Stocks Analysed

£0.97

+5.46% YTD

52W: £0.88 - £1.00

Factor Analysis Summary

Editorial assessment generated from BioPharma Credit PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, BioPharma Credit PLC (BPCR.L) currently holds an overall rank of #7 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include solvency (Altman Z-Score 64.3), where it demonstrates a robust solvency position with conservative leverage and strong balance sheet coverage; valuation (P/E 8.5, dividend yield 576.0%), where it demonstrates compelling valuation metrics, trading at a discount to peer averages on key multiples; and profitability (ROE 11.1%, net margin 82.3%), where it demonstrates strong profitability metrics, ranking in the top quartile for earnings quality and return on capital.

Areas requiring attention include asset efficiency, where poor capital efficiency suggests assets may be underutilised or overvalued on the balance sheet, as well as liquidity, where liquidity is middling and may not suit investors requiring large block execution.

Within the Financials sector, BioPharma Credit PLC sits at composite rank #7, outperforming the Financials peer average (rank 10). Among 7 Financials names in our coverage, it ranks above 4 peers and below 2.

With a composite rank in the top decile (better than 98% of the universe) and 3 factors in the top quartile, BioPharma Credit PLC presents a broadly attractive multi-factor profile, led by solvency and tempered only by asset efficiency.

Strongest Factors

Solvency — Rank 9/280 (top quartile)
Valuation — Rank 34/280 (top quartile)
Profitability — Rank 56/280 (top quartile)

Weakest Factors

Asset Efficiency — Rank 198/280 (below average)
Liquidity — Rank 163/280 (middle of the pack)

Score Analysis

BioPharma Credit PLC is ranked #7 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

93/280

Average Score

Liquidity

Fair163/280

Valuation

Excellent34/280

Profitability

Excellent56/280

Solvency

Excellent9/280

Asset Efficiency

Weak198/280

Mkt Trading

Good112/280

Technical

Good76/280

1. Liquidity

Score: 163/280

How liquid is BPCR and can it meet its short-term obligations?

0/6

liquidity criteria met

Metric

Sector Range

Value

Rank

–

Quick Ratio

N/A

Range: N/A

–

Current Ratio

N/A

3.77xRank 36/280

Range: N/ARank 36/280

–

TTM Operating Cash Flow

N/A

5.14xRank 14/280

Range: N/ARank 14/280

–

Liquidity Coverage Ratio

100-150

N/A

Range: 100-150

–

Intangible Asset Ratio

10 - 30

N/ARank 193/280

Range: 10 - 30Rank 193/280

–

Cash-to-Debt Ratio

N/A

N/ARank 259/280

Range: N/ARank 259/280

Key Liquidity Metrics

Quick Ratio

N/A

Sector: N/A

Current Ratio

3.77x

Sector: N/A

Overall Liquidity Rank

Rank within universe#163/280

Best (1)Worst (280)

2. Valuation

Score: 34/280

Is BPCR undervalued compared to its peers and fair value metrics?

2/7

valuation criteria met

Metric

Sector Range

Value

Rank

–

FY27e P/E

8x - 18x

N/A

Range: 8x - 18x

–

FY26e P/E

8x - 18x

N/A

Range: 8x - 18x

–

FY27e Net Div Yld (%)

3.0 - 8.0

N/A

Range: 3.0 - 8.0

✗

Div Payout Ratio

30 - 55

86.49%Rank 25/280

Range: 30 - 55Rank 25/280

–

Current EV/EBITDA

N/A

7.9xRank 134/280

Range: N/ARank 134/280

✓

Current P/TBV

0.8x - 2.0x

0.90xRank 41/280

Range: 0.8x - 2.0xRank 41/280

✓

Current P/B

0.8x - 2.0x

0.90xRank 50/280

Range: 0.8x - 2.0xRank 50/280

Key Valuation Metrics

TTM P/E

Price-to-Earnings

8.5x

FY26e P/E

Forward estimate

N/A

FY27e P/E

Forward estimate

N/A

Current P/B

Price-to-Book

0.90x

Current P/TBV

Tangible Book Value

0.90x

Current EV/EBITDA

Enterprise Value

7.9x

FY26e EV/EBITDA

Forward estimate

N/A

FY27e EV/EBITDA

Forward estimate

N/A

Dividend

BPCR pays a dividend yield of 576.00%.

Current Yield

576.00%

FY27e Net Div Yield

N/A

FY26e Gross DPS

N/A

FY27e Gross DPS

N/A

3. Profitability

Score: 56/280

How profitable is BPCR relative to its peers?

0/7

profitability criteria met

Metric

Sector Range

Value

Rank

✗

TTM Profit Margin

15 - 30

82.3%Rank 54/280

Range: 15 - 30Rank 54/280

–

T12 FCF Margin

N/A

0.1%Rank 172/280

Range: N/ARank 172/280

–

FY27e RoE

10 - 16

N/A

Range: 10 - 16

–

FY26 EPS Growth

8 - 15

N/A

Range: 8 - 15

–

FY27e EPS Growth

6 - 12

N/A

Range: 6 - 12

–

NIM

1.5 - 3.2

N/A

Range: 1.5 - 3.2

–

Expense Ratio

50 - 65

N/A

Range: 50 - 65

TTM Profit Margin

82.3%

Current RoCE

11.1%

FY27e RoE

N/A

T12 FCF Margin

0.1%

4. Solvency

Score: 9/280

How strong is BPCR's balance sheet and financial position?

0/6

solvency criteria met

Metric

Sector Range

Value

Rank

–

Debt/Eqt

0.5x - 1.5x

N/A

Range: 0.5x - 1.5x

–

Interest Coverage Ratio

N/A

Range: N/A

–

Net Leverage Ratio

N/A

Range: N/A

–

Altman Z-Score (Manufacturing)

N/A

64.35Rank 16/280

Range: N/ARank 16/280

–

Z-Score (Non Manufacturing)

N/A

Rank 16Rank 16/280

Range: N/ARank 16/280

–

CapAdeq Ratio Tier1

13 - 18

N/A

Range: 13 - 18

Key Solvency Metrics

Debt/Eqt

N/A

Net Leverage Ratio

N/A

Interest Coverage

N/A

T12 FCF Margin

0.1%

Altman Z-Score

64.35

Safe Zone

01.812.995+

5. Asset Efficiency

Score: 198/280

How efficiently does BPCR deploy its assets and intellectual capital?

0/5

asset efficiency criteria met

Metric

Sector Range

Value

Rank

–

Efficiency Ratio

50 - 70

N/A

Range: 50 - 70

–

TTM Asset Turnover Ratio

N/A

0.13xRank 204/280

Range: N/ARank 204/280

–

TTM CAPEX/Sales

1 - 3

N/A

Range: 1 - 3

–

Working Capital Turnover

N/A

4.63xRank 89/280

Range: N/ARank 89/280

–

R&D/Sales FY27e

N/A

Range: N/A

Overall Asset Efficiency Rank

Rank within sector peers#198/280

Best (1)Worst (280)

6. Market Trading

Score: 112/280

How liquid and actively traded is BPCR?

1/2

market trading criteria met

Metric

Sector Range

Value

Rank

–

Intraday Sentiment (%)

40 - 75

N/A

Range: 40 - 75

–

10D-Avg v/s 3M-Avg Vol

N/A

109%Rank 50/280

Range: N/ARank 50/280

✓

Avg Directional Index 30D

012 - 45

22.2Rank 106/280

Range: 012 - 45Rank 106/280

–

Parabolic SAR

N/A

0.99Rank 280/280

Range: N/ARank 280/280

–

Stock Rating Rank

N/A

Range: N/A

Market Cap

£1,084,038,224

Enterprise Value

£1,071,451,224

Trading Volume

7. Technical

Score: 76/280

What do the technical indicators say about BPCR?

0/5

technical criteria met

Metric

Chart

Sector Range

Value

Rank

–

CMP v/s 52-WH

1.000.88

-3.4%CMP: 0.97

N/A

-3.4%Rank 37/280

1.000.88

-3.4%CMP: 0.97

Range: N/ARank 37/280

–

CMP v/s 52-WL

1.000.88

+10.3%CMP: 0.97

N/A

10.3%Rank 54/280

1.000.88

+10.3%CMP: 0.97

Range: N/ARank 54/280

–

RSI 14D

045.8 - Bearish100

N/A

45.8Rank 50/280

045.8 - Bearish100

Range: N/ARank 50/280

–

MA50 - MA200

0.95+0.020.97

N/A

BullishRank 201/280

0.95+0.020.97

Range: N/ARank 201/280

–

MACD Rank

Golden Cross

MACD: -0.00

N/A

-0.00

Golden Cross

MACD: -0.00

Range: N/A

RSI (14 Day)

45.8

Bearish

0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA0.97

200 SMA0.95

SignalGolden Cross (Bullish)

MACD-0.00

Risk Metrics

Beta

N/A

3-Yr Std Dev

N/A

5-Yr Std Dev

N/A

Peer Comparison

How does BPCR compare to other Financials stocks?

Overall Rank Comparison

Factor Score Comparison

Stock	Rank	Liquidity	Valuation	Profitability	Solvency	Mkt Trading	Technical
BPCR	#7	163	34	56	9	112	76
MUT.L	#3	128	38	24	56	27	8
RTW.L	#5	116	7	9	145	69	229
RCP.L	#9	179	26	22	59	13	2
AGT.L	#11	108	57	55	72	90	79
TBCG.L	#14	29	55	38	257	129	18
MNTN.L	#15	221	44	74	3	203	262

Similar Stocks

Other top-ranked stocks in the Financials sector

View all

MUT.L

Murray Income Trust PLC

Rank #3Score: 47

RTW.L

RTW Biotech Opportunities Ltd

Rank #5Score: 96

RCP.L

RIT Capital Partners PLC

Schiehallion Fund Ltd

Rank #15Score: 135

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

Methodology Note

The analysis presented for BioPharma Credit PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Strategyland Research Center - strategyland.ukThis report is for informational purposes only. Not financial advice.